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Summary
Lipocalin 2 (Lcn2) is a putative iron-trafficking protein. The aim of this study was to
detenTiine whether Lcn2 plays a role in conditions associated with altered iron metabolism.
Liver Lcn2 rnRNA levels were assessed in mouse models of dietary iron overload and iron
deficiency. Two models of anemia were analyzed, including acute hernolysis induced by
phenylhydrazine treatment and repeated phiebotomies. The Lcn2 response to CoC12-
induced hypoxia and acute and chronic lipopolysaccharide (LPS)-induced inflammation
was also studied. Our resuits show that both types of anemia and hypoxia were associated
with a dramatic increase in liver Ïipocaïin 2 gene expression and serum Lcn2 protein levels.
Both acute and chronic inflammation up-regulate lipocalin 2 transcription and secretion.
The up-regulation of Lcn2 gene expression by anemia or hypoxia suggests an important
physiological role for Lcn2 in iron metabolism and is in une with its recently proposed role
in the transferrin-independent iron delivery pathway. The increase of Lcn2 expression
during acute and chronic inflammation is in agreement with the finding that lipocalin 2-
mediated iron sequestration constitutes a host-defense mechanism of the iimate immune
system.
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Résumé
La lipocaline 2 (Lcn2) est une protéine active ayant pour fonction de favoriser la circulation
du fer dans l’organisme. Le but de cette étude était de déterminer si la Lcn2 contribue ou
non aux conditions associées à un métabolisme ayant un niveau de fer altéré. Les niveaux
d’ARNm hépatique ont été déterminés dans des modèles de souris ayant soit une surcharge
011 une carence en fer. Deux modèles d’anémie ont été analysés, incluant l’hémolyse induite
par la phénylhydrazine, ainsi que les phlébotomies répétées. La réponse de la Lcn2 à
l’hypoxie induite par le CoCÏ2, ainsi que l’inflammation élevée et prolongée induite par les
lipopolysaccharides (LPS), ont également été étudiées. Nos résultats démontrent que les
deux types d’anémie et d’hypoxie sont associés à une augmentation drastique des niveaux
d’expression génique de la Lcn2 dans le foie et des niveaux sériques de la protéine Lcn2. La
relation entre l’expression du gène Lcn2, l’anémie et l’hypoxie suggère que la Lcn2 joue un
rôle important dans le métabolisme du fer et confirme son rôle récemment proposé dans le
métabolisme de transport du fer indépendant de la transferrine.
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I. INTRODUCTION
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I. INTRODUCTION
Iron is an essential element for nearly ail living organisms. It is involved in a large number
of metabolic processes, including oxygen transport, DNA synthesis and electron transport.
However, iron concentrations in body tissues must be closely controlled since too much
iron can lead to tissue injury due to the generation of free radicals, while too littie iron can
lead to anemia. Thus, in light of the multiple biological functions and toxicity of iron, the
existence of a variety of human diseases related to disturbed iron homeostasis is not
surprising.
1. The significance of iron in biological systems
Trou is an essential element in the normal fiinction of ail cells. Many proteins are dependent
on iron to perform their functions. These proteins illustrate the indispensable role of iron in
biological systems. Proteins that contain iron can be classified into tbree categories:
hemoproteins, iron-sulftir proteins and other iron-containing proteins.
1.1. Hemoproteins
Iron forms the core of heme, the main component of hemoproteins. They carry out three
ftinctions: (1) oxygen transport and storage via hemoglobin and myoglobin; (2) electron
transport and energy metabolism via cytochromes; and (3) antioxidant fiinctions through
catalase and peroxidases, and beneficial pro-oxidant functions by myeloperoxidase.
Oxygen transport through hemoglobin is one of the most important functions of iron.
Through the ability of hemoglobin to acquire oxygen by contact and release it when
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needed, hemoglobin in red blood celis (RBC) transports oxygen from the lungs to the rest
ofthe body [1].
1.2. Iron-sulfiir proteins
Iron-sulfur proteins form a second class of iron-containing proteins, in which iron atoms are
bound to sulfur, and they also perform a variety of physiological ftinctions. Rubredoxins
and fenedoxins, for example, play roles in electron transport, and succinate dehydrogenase,
nitrogenase and aconitase participate in redox and non-redox reactions [2].
1.3. Other iron-containing proteins
Other iron-containing proteins refer to a third class of non-heme, non-iron-suifrir iron
containing proteins. These include lipoxygenases, which oxidize fafty acids into
leukotrienes, transferrin, which transports iron in the blood, and ferritin, which stores iron
in ceils.
The diverse range of functions performed by iron-containing proteins provides a sense of
the indispensable role of iron in practically ail forrns of life.
2. Iron toxicity
In hurnan systems, iron is found in two oxidation states: Fe2 and Fe3. At physiological
pH, Fe2 is soluble while Fe3 precipitates as oxyhydroxide polymers. The property of iron
to readily participate in one-electron transfer reactions explains its potential to produce
extremely toxic free radicals. Fe2 can mediate Fenton reactions to produce hydroxyl
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radicals (0H) via the following reaction: Fe2 + H202 —* Fe3 + 0W + 0H. Fe3 can
generate toxic radicals by catalyzing the Haber-Weiss reaction: 0[ + H202 —>
OW+02+OW [3]. Hydroxyl radicals can cause damage to DNA, proteins, polyunsaturated
fatty acids, mitochondrial DNA or lysosomes [4, 5].
The severity of iron-mediated toxicity is correlated with the concentration of low molecular
weight iron in the labile iron pool within ceils. fron accumulation in tissues can increase the
arnount of low molecular weight iron within the pool, thus catalyzing the production of
more toxic free radicals than are present in healthy individuals, in whom iron is stored as a
cofactor for different proteins to prevent its toxic effects.
The dismption of normal iron metabolism has been shown to lead to a variety of iron
disorders, ranging from anemia to iron overload to neurodegenerative disorders. Thus,
systernatic and cellular iron homeostasis must be properly maintained in the body in order
to allow iron to be made available for physiological functions, and, at the same time, avoid
its toxicity.
3. Disorders of iron metabolism in humans
The importance of maintaining iron homeostasis is clearly demonstrated by the existence of
a group of diseases caused by dismrbed iron metabolism.
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3.1. Iron deficiency disorders
When iron is not available for ceils involved in RBC production, hemoglobin synthesis is
reduced, resulting in a reduction in the rate of erythropoiesis as well as the production of a
microcytic red blood celi population. In the early stage ofmicrocytic anemia, symptoms are
often not apparent. In differential diagnosis, four types of microcytic anemia are
considered: iron-deficiency, iron-transport deficiency, iron-utilization anernia, and iron
reutilization anemia (anemia of chronic disease).
3.1.1. Iron deficiency anemia
Iron deficiency anemia has had many names: anemia of chronic blood loss, hypochromic
microcytic anemia, chlorosis, hypochromic anemia of pregnancy, infancy, and childhood
[6].
The rnost common cause of anemia is blood loss from the gasterointestinal tract. Women
may bleed from menstrual loss. Pregnant women may lose iron to the developing fetus.
Increased iron requirement, such as in infants less than two years of age, and reduced iron
absorption, as in the case of gastrectomy, may also cause iron deficiency [7].
3.1.2. Iron-transport deficiency anemia
Atransferrinemia.
Iron-transport deficiency anemia is a rare disease caused by reduced levels oftransfeirin. In
these individuals, iron caimot be transported from the intestine and liver to the bone
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manow for erythropoiesis. Hemosiderosis of lymphoid tissue, particularly along the
gastrointestinal tract, often occurs in this type ofanemia [8].
3.1.3. Iron-utilization anemias
Iron-utilization anemias include diseases such as hemoglobinopathies, primary thalassemia,
and sideroblastic or myelodysplastic anemia [9]. Iron-utilization anemias are caused by the
abnormal utilization of iron for hemoglobin synthesis, despite the normal presence of iron
in the mitochondria of developing RBCs. Dyspoiesis increases the intramedullary death of
RBCs, paradoxically leading to erythroid hyperpiasia with a relative or absolute
reticulocytopenia. In feffokinetic studies, radiolabeled iron rapidly distributes from blood to
the bone manow, but fails to reappear in developing RBCs at a normal rate. Ineffective
erythropoiesis is thus the main characteristic ofthese anemias.
3.1.4. Iron-reutilization anemia
Anernia of chronic disease (ACD), also called inflammation anemia, is the second most
common form of anemia. In ACD, bone marrow erythropoiesis does not respond
appropriately to anemic conditions. The early stages of the disorder show symptoms of
normocytic anemia whereas microcytic anemia is characteristic ofthe later stages [10].
ACD results from complications of many chronic disorders such as infection, inflainmatory
disease, and cancer. Three pathophysiologic mechanisms are believed to be involved: (i)
increased iron retention and storage within the reticuloendothelial system can induce
hypoferremia, which limits iron availability to erythrons for hemoglobin (Hb) synthesis; (ii)
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deficient erythropoiesis resulting from decreased erythropoietin (EPO) production or
reduced bone marrow responses to EPO; and (iii) red blood celi suiwival times are reduced
through mechanisms that are not entirely clear. In ail three mechanisms, inflarnmatory
cytokines are involved, including interleukin-1 (IL-l) and turnor necrosis factor Œ (TNF-a).
3.2. Iron overload diseases
Chronic iron overload is characterized by an increase in tissue iron deposition either in a
focal site or overail in tissues. The tenu liemosiderosis is cornmonly used for tissue iron
overload. More severe states of iron ovcrload (greater than five grams of iron present in the
body) are referred to as hemochromatosis. Hereditary hemochromatosis (HH), caused by
mutations in the hereditary hemochromatosis gene (HFE), must be differentiated from
other genetic iron overload, non-genetic iron overload, and increased iron storage of
undetenuined etiology (Table 1).
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Table 1. Classification of hemosiderosis and hemochromatosis.
1. Focal hemosiderosis
1. Pulmonary (idiopathic)
2. Renal
3. Hepatic (porphyria cutanea tarda)
II. Prirnary (genetic) hemochromatosis
1. HFE HH [herediatory hernochrornatosis HFE)] (HH Type 1)
2. Juvenile hemochromatosis [Hernojuvelin (HJV) and Hepcidin (Harnp)J (HH Type 2)
3. HH Type 3 [transferrin receptor 2 (‘T/R2)]
4. HH Type 4 [Ferroportin] (FF1)]
5. African iron overload
6. Atransferrinemia [transferrin (Tj)]
7. Neonatal hemochromatosis
8. Aceruloplasminemia [ceritioplasmin (Cp)J
III. Secondary hemosiderosis or hemochromatosis
1. Congenital hemolytic anemias
2. Defective hemoglobin synthesis (thalassernia)
3. 1ncreased parenteral iron intake, repeated transfusions
4. Iron dextran injections
5. Jncreased iron absorption (increased iron intake)
i. Ethiopian (teffcereal) hemosiderosis with hemochromatosis
ii. Oral iron therapy with hemosiderosis or hernochromatosis
Iii. Kashin-Bek disease with hemosiderosis
3.2.1. Focal hemosiderosis
Focal hemosiderosis occurs mainly as a result of other diseases. Lungs and kidneys are the
most cornmonly affected sites [11, 12]. Pulmonary hemosiderosis is caused by recurrent
pulmonary hemorrhage resulting in iron accumulation. Renal hemosiderosis is caused by
various forms of hemolysis resulting in Hb deposits in the glomerulus. The renal
parenchyrna is able to maintain its normal ftinction, but severe hemosiderinuria causes iron
deficiency.
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3.2.2. Type 1 HH tHFE-associated)
Type 1 hemochromatosis is an autosomai recessive iron disorder. A candidate gene for
hemochromatosis (HFE) was found to be localizcd in the human chromosome 6p2l [13].
C282Y and H63D are two important mutations found in HFE [14]. The C282Y
homozygote mutation has been found in 60—100% of Type 1 HH patients in the European
population, and the H63D mutation is found in approximately 16% of these [13, 14]. HFE
encodes a protein homologous to major histocompatibility compiex (MHC) ciass I
molecules. Although the HFE protein retains many of the structural features of ciassicai
class 1 molecules, its inward dispiacement ofthe cd domain helix prevents peptide binding.
Given that the HFE protein interacts with transfenin receptor 1 (TfR1), a moiecule that
plays a central foie in ceiiuiar iron uptake [15], HFE is thought to influence iron uptake in
celis. The body obtains iron tbrough duodenai iron absorption. Duodenai iron absorption
efficiency is reiated to the iron-sensing property of crypt celis, which receive signais about
the body’s iron requirements, in part through the binding of transferrin to the HfE/TfRÏ
complex. HFE mutations cause signaling of misinformation regarding iron requirements in
the body. The consequence of this is excessive intestinal absorption of iron, which in tum
ieads to a progressive iron ioading in the parenchymal ceils of important organs such as the
liver, pancreas and heart. This can resuit in various iilnesses such as liver disease, diabetes
meiiitus and cardiomyopathy [16]. Phlebotomy is the most efficient method for removing
excess iron in type 1 HH patients.
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3.2.3. Non-TIFF HH
Juvenile hemochromatosis (Type 2 HH)
Type 2 HH is a rare disorder originally identified in a gene heredity study of several Italian
farnilies [17]. Juvenile hemochromatosis patients have accelerated iron loading rates as
compared with Type 1, HFE-associated HH [17]. Due to the rapid iron loading in Type 2
HH, cardiomyopathics and endocrinopathies occur more cornmonly than liver dysftinction.
Most individuals with juvenile hemochromatosis do flot survive beyond thirty years of age
due to heart failure. Gene association studies in Type 2 HH have confirmed that the
underlying Hemojuvelin (HJV) gene is located on human chromosome lp [1$]. HJV mutant
patients have decreased hepcidin levels, which suggests that HJV may modulate hepcidin
expression [19]. In addition, juvenile hemochromatosis was also found to be associated
with mutations of Harnp, located on 19q13, which encodes hepcidin [20].
Type 3 HH
Type 3 HI-I is causcd by mutations in the transferrin receptor 2 (Tffl2) gene, and is an
autosomal recessive disease. From fifteen Italian patients in five different families, four
different mutations of TJR2 have been reported. Patients show a chronic increase in iron
absorption resulting in high iron accumulation in the liver, heart and pancreas, suggesting a
disniption in intestinal iron absorption due to the TfR2 mutation [21].
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Type4HH
Type 4 HH, an autosomal dominant disease, is caused by ferroportin 1 (FF1) gene
mutations [22, 23]. Iron concentrations increase in the liver, heart and pancreas in type 4
HH patients. Liver macrophages contain high amounts of iron and serum iron is relatively
low. Two hypotheses regarding type 4 HH have been put forward at present. The loss-of
ftmction hypothesis suggests that FF1 mutations impair iron recycling by macrophages,
subsequently delivering abnormal signais to the intestine (mechanism as yet not
understood), resulting in increased iron absorption and subsequent iron overioad [23]. The
gain-of-function hypothesis suggests that FF1 mutations increase iron absorption in the
duodenum [22]. In type 4 HH patients, since iron overioad is combined with anemia,
phlebotomy treatment is not recommended.
African iron overioad
In the sub-Saharan region of Africa, approximately 10% of the population has a
predisposition for iron overload, also referred to as Bantu siderosis [24]. A risk factor for
African iron overioad is thought to be dietary iron intake from traditionally brewed beer.
Since the prevaience of iron overioad in this region is high and flot ail beer drinkers are
affected by iron overioad, it is difficuit to trace the inheritance pattem. Statisticai data,
however, suggests that it is an autosomal dominant inherited disease, and the HFE gene has
been exciuded as the causative gene for African iron overioad [25]. In African iron
overioad patients, liver disease occurs more commonly than cardiomyopathy or diabetes. In
addition, iron accumuiates in hepatic Kupffer ceiis and spleen in large amounts, suggesting
a defect in iron recyciing by the reticuloendothelial system [26].
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Atransfeninemia
Atransfeninemia is a very rare disease in which transferrin mutations cause impaired
erythropoiesis, but iron accumulation is high in the liver due to an increase in non
transfenmn bound iron (NTBI) [8, 27].
Neonatal hemochromatosis
Neonatal hemochromatosis is a rare, poorly characterized disease that occurs in newbom
infants, with high iron accumulation in the liver, heart andlor pancreas [28]. Liver failure
may occur. It is unclear whether iron overload initiates the disease, or if other causes lead to
iron overload [29]. Neonatal hemochromatosis is usually jointly present with other
congenital diseases with similar liver manifestations, which suggests that it is a
heterogenous disorder [30]. Familial cases have not been reported, and HFE gene mutations
are not found in neonatal hemochromatosis. Liver transplantation is the only efficient
therapy and has been found to prolong life in several cases [31].
3.2.4. Secondary iron overload (non-genetic)
Secondary iron overload includes transfusional iron overload and iron overload attributed
to defective erytbropoiesis (congenital hemolytic anemias or hemoglobinopathies). In
thalassemia major patients given transfusions without chelation, iron accumulation in the
body is accelerated. Transfusional iron accumulation leads to progressive damage of the
heart, liver and endocrine glands [32]. Iron overload-induced heart disease determines the
12
survival rate of the transfiised patients [33]. Liver disease is the second leading cause of
death in these cases [34].
3.2.5. Iron overload ofundetermined origin
Some liver diseases are associated with elevated iron storage, for example, alcoholic liver
disease, non-alcoholic steatohepatitis, and chronic hepatitis C [35]. The mechanisms are
unknown. Although the patients do not have a genetic hemochromatosis background, iron
unloading management may improve tiver function [36].
3.2.6. Neurodegenerative disorders related to iron metabolism
Neurodegenerative diseases related to iron metabolic disorders can be classified into two
categories based on the underlying iron defect: mitochondrial iron disturbance and brain
iron disturbance. Mitochondrial iron disturbance is linked to friedrcich’s ataxia and X
linked sideroblastic anernia with ataxia. Brain iron disturbance is related to
neurofeiritinopathy, pantothenate kinase deficiency and acerulosplasminaemia.
Friedreich’s ataxia
Friedreich ataxia is an inherited lethal disease, and is characterized by spinocerebellar
degeneration, cardiomyopathy and diabetes mellitus. In gene linkage studies, Friedreich’s
ataxia was found to be associated with the gene encoding frataxin located on chromosome
9q [37]. Expansions of a trinucleotide repeat in an intron are usually found in patients, but
point mutations have arc also been identified [37]. Affccted patients usually have defects in
both alleles of the frataxin gene, ultimately leading to decreased frataxin levels. Frataxin is
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a mitochondrial protein whose exact fiinction remains undetermined. Lack of frataxin
homologues in yeast and mice leads to increased mitochondria toxicity, due to iron
accumulation, elevated sensitivity to oxidative stress and depletion of iron-sulfiir proteins
[38, 39].
X-Iinked sideroblastic anemia with ataxia
X-linked sideroblastic anemia with ataxia presents as mild microcytic anemia, bone manow
sideroblastosis and nonprogressive cerebellar ataxia [40]. It is caused by an isoleucine to
methionine substitution (1400M) in the ATP-binding cassette transporter 7 (ABC7) gene,
locatcd on chromosome Xq. The exact pathogenesis of this disease is unknown. However,
since Atmlp, the S. cerevisiae homologue of human ABC7, plays a role in iron export in
yeast mitochondrion [41], iron accumulation within human mitochondria is thought to
result from the loss-of-function mutation in A3C7.
X-linked sideroblastic anemia
X-linked sideroblastic anemia with ataxia is distinct from the non-neurodegenerative
classical X-linked sideroblastic anemia, which is an X-linked recessive disease caused by
mutations in the erythroid aminolevulinic acid synthase (e-ALAS) gene located on
chromosome Xp [42]. The e-ALAS enzyme catalyzes the first step of heme synthesis.
Dysftinctions in e-ALAS cause a defect in heme synthesis, leading to iron accunuilation in
the mitochondria of erythroid precursors. Impaired erythropoiesis induces increased iron
absorption from the intestine, resulting in iron overload. 11e anemia is usually nonuocytic;
microcytic anemia is less common [43].
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Neurofenitinopathy
Neurofenitinopathy is a late-onset disease of the basal ganglia, in which patients present
with extrapyramidal features sirnilar to those found in Parkinson’s disease. Patients with
neurofelTitinopathy usually have abnormal iron and fenitin aggregates in the brain.
Mutations in the ferritin light chain gene leads to a structural change in the encoded protein.
The resultant fenitin dysfiinction causes iron release from ferritin and iron accumulation in
axons or synapses. This iron accumulation enhances oxidative stress in the neuron and
resuits in neurodegeneration [44].
Pantothenate kinase-deficiency
Pantothenate kinase (PANK2)-deftciency is an example of a brain iron-overload disease
involving a gene whose function is not related to iron metabolism. PANK2-deficiency
usually develops within the first two decades of life, and clinically presents as dystonia,
pigmentary retinopathy, optic atrophy, and high concentrations of iron in the globus
pallidus [45]. PANK2 gene mutations cause a block in the coenzyme-A biosynthesis
pathway. The subsequent increase in cysteine concentrations in the brain leads to iron
accumulation due to the iron-chelating properties of cysteine. The increased free radical
production and oxidative stress derived from iron accumulation result in neurodegeneration
[46].
Acerulosplasminaemia
Aceniloplasminemia is a rare disease, in which decreased ceruloplasimin levels in plasma
cause an inability for Fe2 to be oxidized to Fe3, which is critical for the binding of iron to
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transfenin. In acerulosplasminaemia, mutations in the ceruloplasmin gene ieads to a
decrease in iron released from neurons of the retina and the basal ganglia. Consequently,
regional iron accumulation enhances neuronal oxidative stress, resulting in progressive
neurodegeneration [47-49].
All the disorders mentioned in this section demonstrate the importance of maintaining iron
horneostasis. They emphasize the importance of understanding the principles regulating
iron rnetabolism at thc cellular and systemic levels. Within the past 10 years, advances in
molecular biology techniques have permitted a dramatic increase in the information
available on the various steps of iron metabolism: iron uptake, transport, storage, export
and utilization.
4. Cellular iron homeostasis
Cellular iron homeostasis needs to be tightly controlled through iron uptake, storage and
export. Thus, the molecular understanding of each step of iron metabolism helps elucidate
the principles of normal iron homeostasis and the mechanisms of iron disorders.
4.1. Iron uptake
Iron uptake is necessary for ail cells. This section will detail identified pathways of cellular
iron uptake: (j) classic transferrin-dependent iron uptake, which is used by almost all cells;
(ii) ceil-type specific iron uptake in macrophages and enterocytes; and (iii) transferrin
independent iron uptake, which piays a minor role.
16
4.1 .1. Transferrin-dependent iron uptake
Transferrin is the most important iron-transporting protein in the blood, and it binds iron
with high affinity. In normal situations, ail circulating iron is bound to transfenmn. Two
ftinctions are served by this transferrin-iron binding: (j) the prevention of free-iron derived
toxicity through binding of fe3 in the blood; and (ii) the facilitation of iron transport in the
plasma and iron uptake into ceils. Plasma transfenmn is mainly synthesized in and secreted
from the liver into the blood, where it mediates the exchange of iron among the various
sites of absorption, recycling, utilization, and storage.
The delivery of transferrin-bound iron into the cell is mediated by transferrin receptors
located on the ceil surface. Receptor-mediated endocytosis is the classical pathway used by
almost all mammalian cells in order to obtain iron [50-52]. Transferrins and the transferrin
receptor 1 (TfR1) are the components of this classical iron uptake and transferrin-recycling
pathway (Figure 1). Cell surface transferrin receptors bind to the iron-transfenmn complex
with high affinity under neutral pH conditions [531. Once the transferrin receptor-bound
iron-transferrin complex has been endocytosed, it is intemalized into endosomes with a
neutral pH. ATP-dependent proton pumps subsequently acidify the endosomal interior to
pH 5.5 [54-5 7], which facilitates the dissociation of fenic iron (Fe3) from transferrin. The
fenic iron released within the acidified endosomes is converted to ferrous iron and then
transported by the divalent metal transporter 1 (DMTY) into the cytoplasm [58].
Transfenmns remain bound to their receptors after the release of iron in the acidified
endosomes, and are recycled to the cell surface. In the neutral (pH 7.4) environment at the
cell surface, the non-iron bound transfenmns lose affinity for their receptors, promoting their
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dissociation. Transfenin is thus recycled back into circulation [51, 55]. The recycling
process of transfenins enables one transfenin to be re-used up to one hundred times over
the course ofits eight-day haif-life.
Transfenin receptor 2 (TfR2) and cubilin are ftvo alternative receptors for transfenin. TfR2
is bighly homologous to TfR1, yet it binds transferrin with a lower affinity [59]. The fact
that TfR2 is only expressed in the liver and cannot rescue TfR1-mutant mice from early
death suggests that TfR2 and TfR1 do not share the same roles [60, 61]. Cubilin is a novel
potential transfenin receptor, which bas been shown to mediate endocytosis of the
transferrin-iron complex, albeit only in the proximal tubules of the kidney and the yolk sac
[62].
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Figure 1. The transferrin (If) cycle. Iron-loaded transferrin (fe2-Tf) binds to transfenmn
receptors (TIR), which associate with 32m-HFE molecules on the ceil surface. Apo
transfenin (Apo-Tf) and transferrin receptors can be re-used for further cycles of iron
binding and iron uptake.
4.1.2. Iron uptake by reticuloendothelial (RE) macrophages
Macrophages can obtain iron in three ways: (i) transferrin receptor-mediated iron uptake;
(ii) ceil surface receptor CD163-mediated hemoglobinlhaptoglobin complexes uptake [63];
and (iii) phagocytosis of senescent or damaged RBC (Figure 2). In the latter two pathways,
hernoglobin is broken down by heme oxygenase 1. lion released from hemoglobin is
subsequently transported from the phagosome into the cytoplasm by DM11. In the
cytoplasrn, iron will either be stored in fenitin or transported back into the blood by
ferroportin 1. Macrophages are the most important cells for iron recycling because they can
obtain iron from RBCs and release digested iron back into the circulation for the
development of erythron precursors.
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Macrophage Erythrocyte
Figure 2. Macrophage iron uptake and recycling. Macrophages can obtain iron by three
different mechanisms: (i) TfR-mediated uptake of transferrin-iron complexes; (ii) CD 163-
mediated acquisition of the haptoglobinlhemoglobin complex; and (iii) phagocytosis of
senescent RBCs. In erythroid precursors, iron is taken up for heme biosynthesis through a
TfR-mediated rnechanism. Nramp 1: natural resistance-associated macrophage protein 1,
Hp-Hb: hemoglobinlhaptoglobin complexes.
4.1.3. Iron uptake by intestinal absorptive ceils
Dietary-derived iron is the normal source of exogenous iron. The intestine thus performs an
important function in absorbing iron from exogenous sources. The developing enterocyte
and mature enterocyte obtain iron through two different pathways. In the duodenum, the
apical villus enterocyte matures and migrates from developing crypt ceils. The former can
absorb exogenous iron, whereas the latter does not. Crypt ceils can take up iron only
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through the transferrin receptor-mediated pathway. This section will focus on iron
absorption by the apical absorptive celis of the duodenum. Low molecular weight iron and
heme-iron are the two forms of iron that can be absorbed in this manner.
The process of transporting dietary-derived low molecular weight iron across the intestinal
absorptive celis occurs in three steps (Figure 3): (i) uptake of iron through the apical
membrane; (ii) distribution of iron in the ceil and transport of iron to the basolateral
membrane; and (iii) the transfer of iron through the basolateral membrane into the blood
[64, 65]. In the first step, dietary ferric iron (fe3) is reduced to fenous iron (Fe2) by the
ferric reductase Dcytb, which is located at the apical membrane [66]. Fe21 is then
transported into the celi cytoplasm by DMT1. Iron thus joins the intracellular labile iron
pool (LIP) [67], from which iron either is directed to ferritin, where iron is stored, or is
transported ftirther across the basolateral membrane into the blood by the iron exporter
called fenoportin 1 [68].
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Figure 3. The process of intestinal iron absorption. Dietary iron is taken up through the
apical membrane of the intestine into the cytoplasm. lion is then transferTed across the
basolateral membrane into the blood. Only crypt ceils of the intestine obtain iron via the
TfR-mediated pathway. Heph: hepheastin.
It is noteworthy that iron contained in heme derived from meat (containing hemoglobin,
myoglobin and other heme proteins) is another important source of iron. Dietary heme iron
accounts for approximately 30% of the total dietary iron in North American and Europe
[69]. Heme-derived iron can be released by heme oxygenase 1 in the enterocyte, although a
heme receptor at the apical membrane has not yet been identified.
An alternative ferric iron uptake mechanism has been identified for dietary iron absorption,
refeiied to as the integrin-mobilferrin pathway (IMP). IMP transports only ferric iron
(Fe3j, and no other metals, into enterocytes [70]. Proteins associated with this pathway
includc mobilfenin, f33-integrin and flavin monooxygenase, whose macromolecular
complex (520 kDa) is called parafenitin. The IMP complex is only found in enterocytes,
and it is not known to what extent this pathway contributes to dietary iron absorption.
4.1.4. Transfenin-independent iron uptake
The existence of transfenin-independent iron uptake is suggested by two classes of iron
disorders: transferrin shortage (atransfeninemia) and iron overload (hemochromatosis,
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thalassemia). In hypotransferrinernia the reduction of transferrin levels leads to severe
hypochromic microcytic anemia and massive iron loading in ail non-hematopoietic tissues,
in particular in the liver and pancreas [71-73]. In hereditary hemochromatosis and
transfusional thalassemia, two iron overload diseases, non-transferrin bound iron (NTBI) is
found in the blood [74-77]. NTBI distributes iron into tissues different from those covered
by transferrin-bound iron [74-77]. Furthermore, three pathways have been identified which
support the existence of a transferrin-independent iron uptake, mediated by ferritin, L-type
Ca2 channcls, and lipocalin 2.
Feiiitin-rnediated iron uptake is supported by several studies. In rats, when ferritin
containing radiolabeled iron is injected into the circulation, iron is taken up and stored in
the liver [78]. In addition, the liver expresses ferritin receptors, and hepatocytes take up
iron-containing ferritin via receptor-mediated endocytosis [79].
The L-type Ca2 channel provides a pathway for iron entry into cardiomyocytes. This
pathway is organ specffic, because L-type Ca2 channels are specffic to cardiomyocytes.
This pathway is important in iron overload conditions, as high concentrations of NTBI can
utilize this pathway to enter the heart, leading to cardiac iron accumulation, and consequent
cardiornyopathy [$0].
Lipocalin 2 is a newly identified putative iron transporter. Lipocalin 2 is the mouse
homologue of the human neutrophil gelatinase-associated lipocalin (NGAL) gene.
Structural analyses have shown that lipocalin 2 can bind siderophores (bacterial-derived
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iron binding compounds) and iron [81]. Lipocalin 2-mediated iron transport has been
shown to deliver amounts of iron sufficient for the regulation of iron-regulated gene
expression in several celi unes [$2], including mouse embryonic kidney collecting duct
celis, human Wilms tumor kidney ceils, dog kidney collecting duct ceils, rat embryonic
kidney epithelial celis and mouse kidney stroma celis. Lipocalin 2-mediated iron transport
can also provide iron for the development of the mesenchyme into epithelia during kidney
development [$2].
4.2. Iron storage
When iron is present in the cytoplasm, ferrous iron is carried by a carrier molecule to the
labile iron pool (LIP). This iron carrier molecule has not been identified, because of the
very srnall amount of iron in the LIP. In the cytoplasm, iron diffuses to various intracellular
cornpartments, such as the mitochondria for heme biosynthesis, or to ferritin for storage.
ferritin is a heteropolymer complex, composed of twenty-four subunits of H (heavy/heart)
and L (light/liver) chains [$3]. The central cavity of ferritin can store up to 4500 iron ions
[83]. The composition of ferritin varies with the ratio of H and L chains, depending on the
organ in which it is found (Figure 4). ferritin found in the liver and spleen is rich in L
chains, which are associated with high iron storage, whereas ferritin found in the heart is
rich in H-chains, which are associated with high iron utilization [$3, 84]. ferritin thus has a
variable iron storage capability, with a high H:L ratio when heme synthesis or cell
proliferation increases [54, 85]. The degradation of ferritin and the associated release of
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iron facilitate the mobilization of iron for cellular utilization, and is associated with
lysosomes [86, 87].
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Figure 4. The composition of ferritin. Each ferritin molecule is composed of 24 chains,
either L or H chains. The ratio of L and H chains in fenitin varies among organs.
Furthermore, the L/H chain ratio in ferritin can be modified in response to iron overload or
inflammation.
4.3. Iron export
Duodenal enterocytes, macrophages, hepatocytes and other types of celis have similar
mechanisms for releasing iron in order to meet the iron needs of the whole body and also to
maintain iron balance within celis. Ferroportin 1 (FP 1) is a ubiquitously expressed protein.
Fenoportin 1 fimnctions as a cellular iron exporter, by transporting iron from the cytoplasm
into the blood [88, 89]. However, ferroportin 1 needs the cooperation of a ferroxidase to
perform this frmnction (Figure 5). Two types of copper ferroxidases are found in the body:
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ceniloplasmin (Cp) and hephaestin, both of which oxidize Fe2 into Fe3, for Fe3 binding
to transferrin in the blood.
Hephaestin is the homologue of the plasma protein cemloplasmin. Arnino acids involved in
copper binding and disulfide bond formation are conserved between cemioplasmin and
hephaestin. Unlike ceniloplasmin, hephaestin is a trans-membrane protein. Since
ceniloplasmin circulates in the blood and hephaestin is expressed only in the intestinal villi,
ceniloplasmin can facilitate iron export from non-intestinal cells while hephaestin mediates
intestinal iron export. Sflidies in hephaestin knockout mice have shown that ceruloplasmin
cannot replace the role of hephaestin in the process of enterocyte iron export [90, 91].
The cernioplasmin protein is a member of the multicopper oxidase family, which can utilize
copper to catalyze biochemical reactions [92]. Since ceniloplasmin contains greater than
95% of the copper found in plasma, it was first thought to be involved in copper
metabolism. However, cemioplasmin knockout mice exhibited normal copper metabolisrn
during copper absorption, transportation, distribution, and excretion steps [93]. These
evidence suggest that copper is only required for ceruloplasmin to carry out ferroxidase
frmnctions, and that cemioplasmin does not play an essential role in copper metabolism.
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Figure 5. Iron export facilitated by ceniloplasmin (Cp) and hephaestin (heph).
Ceruloplasmin and hephaestin are structurally similar, and both have ferroxidase activity,
which can oxidize Fe2 into Fe3.
4.4. Cellular iron homeostasis
Cellular iron homeostasis is regulated by the iron responsive proteinliron responsive
elernent (IRP/IRE) system in the ceil (Figure 6). IREs are found in the 3’- or 5’-
untranslated inRNA regions of several critical proteins involved in iron rnetabolism,
including ferroportin 1, DMT1, ferritin, and TfRY [94, 95). IRPs normally exist in the
cytoplasrn as cytosolic aconitases. IRPs can bind to IREs to regulate the translation of
proteins.
The affinity of JRPs to bind IREs is dependent upon the iron concentration in the labile iron
pool (LIP). Under high iron concentrations, IRPs are fihled with a 4Fe-4$ cluster that
prevents the binding of IREs. Under low iron conditions, the 4Fe-4S cluster dissociates
from IRPs, which can then bind to IREs.
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Through the binding of IRPs to IREs, the IRP/IRE system post-transcriptionally controls
protein synthesis. The location of IREs on either the 5’- or 3’-untranslated region of
mRNAs determines the consequences of IRP-IRE binding. For example, in ferritin, where 1
IRE is located in the 5’-untranslated region of the mRNA, the IRP/IRE binding blocks the
translation pathway, thus decreasing ferritin synthesis. Conversely, in transferrin receptor 1,
where IREs are locatcd to the 3’ -untranslated region of the mRNA, the IRP/IRE binding
stabilizes the mRNA, and thus enhances TfRl synthesis.
Through the regulating activity of the IRP/IRE system, the up- or down-regulation of iron
responsive genes enables the celi to maintain proper iron homeostasis. For example, when
the iron concentration is high in the LIP, ferritin protein synthesis is up-regulated to store
more iron, while TfRl is down-regulated, reducing the uptake of iron.
The IRP/IRE system can be influenced not only by iron concentrations, but also by nitric
oxide (NO) levels, oxidants and hypoxia [96, 97]. These factors provide the ceil with a
greater degree of control over iron levels via a complex seif-regulation mechanism.
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Figure 6. The IRP/IRE regulation system. The affinity ofIRPs for IREs depends on the iron
level in the labile iron pool. When the iron level is low, the binding of IRPs to IREs at the
5’-untranslated region blocks mRNA translation, while binding of IRPs to ifiEs at the 3’-
untranslated region increases mRNA stability, and thus protein synthesis.
5. Systemic iron homeostasis
5.1. Distribution of iron in aduits
The average human has on average 4g of total body iron and approximately 1 -2mg of iron
are lost daily from the epithelial surfaces of the gut and skin and, in females, through
menstruations (figure 7). These daily losses are replenished through the transfer ofingested
dietary iron to the portal circulation. Internai iron requirements, for the production of
hemoglobin, are met by recycling iron from the destruction of RBCs by the
reticuloendothelial (RE) system and subsequent release of iron into the plasma, where iron
is transported while bound to transferrin (If) [9$]. Excess iron is stored in ferritin in the
liver in a non-toxic form that can be mobiiized as required. Under normal conditions, liver
iron stores are close to 1g, but growing chiidren and menstruating women have reduced
liver iron stores due to their increased iron requirements [99]. Another smailer proportion
of iron is located in muscle myoglobin and body enzymes.
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Figure 7. Distribution of iron in aduits. Iron is absorbed from the duodenum, transported
into the plasma, recycled by macrophages, utilized by erythrocytes and enzymes, and stored
in the liver. Iron regulatoiy factors can change the ftinction of these organs and celis, thus
redistributing iron to establish a new iron homeostasis in the body.
5.2. Iron regulators
5.2.1. The four iron regulators
Systemic iron homeostasis is maintained through the control of iron absorption, iron stores
and iron recycling to meet the iron demands of erythropoiesis and iron-dependent enzyme
activity.
Four iron regulators can change iron mobilization and iron redistribution in the body: (j)
The iron stores regulator refers to the amount of iron stored in the body [100]; (ii) the
hypoxia regulator refers to oxygen insufficiency in the body; (iii) the erythropoetic
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regulator refers to the need for the production of RBCs; and (iv) the inflammatory regulator
refers to infection and inflammation stimuli.
In normal aduits, acute iron requirements are satisfied by the release of stored iron from the
liver and recyclcd iron from macrophages. When the release of iron from body stores
cannot meet the iron demand, as is the case in iron deficiencies, iron absorption from the
intestine is accelerated. The erythropoetic regulator can dramatically increase iron
absorption from the intestine. It can even override the effect of the stores regulator. For
instance, in transferrin-mutant mice, hypotransfeninemia causes insufficient iron delivery
into erythroid precursors. These mice develop severe anemia, which requires increased iron
absorption. Paradoxically, the mouse also has iron overload in the body, which leads to a
decrease in iron absorption. In this case, the erythropoetic regulator will dominate the stores
regulator, and thus increased iron absorption from the intestine continues [101].
The activation of the hypoxia regulator can also increase iron absorption from the intestine,
which produces an effect similar to that of the erythropoetic regulator. However, the
interaction of the hypoxia regulator with the other regulators has not yet been ffilly
investigated.
Infection and inflammation is another strong regulator of iron metabolism. The
pathophysiologic response of iron metabolism to inflammation is to withhold iron from
invading bacterial pathogens, through reducing iron release from the liver and the
macrophages and by suppressing intestinal iron absorption, thus decreasing serum iron
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levels. The inflammatory regulator can override the erythropoetic regulator. For example,
in anemia of chronic diseases, inflammatory cytokines reduce bone marrow RBC
production [102-104]. $uch anemia activates the erythropoetic regulator to increase iron
absorption from the intestine. Paradoxically, at the same time, the inflammatory regulator
produces a decrease in iron absorption. In this contradictory situation, the inflammatory
regulator dorninates the erythropoetic regulator, ultimately resulting in a decreasc in
intestinal iron absorption.
This hierarchy between iron regulators predicts the existence of messengers circulating in
the blood needed to deliver signais among the sites of iron utilization, storage, absorption,
and recycling, to conectly coordinate the efficiency of iron mobilization arnong these sites.
5.2.2. Hepcidin, a putative iron messenger
Hepcidin is a newly identified iron messenger. It is a small peptide secreted by the liver and
excreted through the kidneys [105-107]. Hepcidin can respond to ail four known iron
regulators. For example, hepcidin expression is increased by iron overload diets in rodents,
which represents an iron store regulator [107]. It is also reduced in non-anemic hypoxia, a
hypoxia regulator [108], and is eievated in response to anemia, an erythropoetic regulator
[109]. Finally, hepcidin expression is increased in different types of inflammation in mice
and humans, which represents an inflammatory regulator [10$-110].
Hepcidin functions as a regulator of iron absorption in the intestine and iron release from
macrophages, as has been demonstrated in hepcidin-knockout mice and hepcidin-transgenic
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mice. Hepcidin depletion in knockout mice is associated with increased body iron [111,
112]. lncreased hepcidin levels in transgenic mice resuits in iron deficiency [112]. Thus, the
level of serum hepcidin provides a counterbalance to the level of body iron stores. This
regulation may be explained by the recent finding that hepcidin regulates iron efflux via its
binding to ferroportin 1 (FPY). This binding subsequently leads to FPY intemalization and
degradation, resulting in a decrease in FP1 concentration at the ceil surface [113].
5.3. Animal models
Studying animal models takes advantage of the similarities between human and rodent iron
rnetabolisrn regulation. $pecific gene dismptions in rodents, including targeted disruptions
and spontaneous mutations, have provided crucial information about each gene involved.
Studying the function of targeted genes in these rodents has extended our knowledge of the
pathways of iron metabolism at the molecular level and the defects that occur in iron
rnetabolism disorders. (Table 2)
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Table 2: Useftil rodent models for understanding iron metabolism and related diseases.
Iron phenotype human diseaseMouse model Gene affected
mode ling
Tncreased iron absorption, iron overload,
Hfe Hfe hepatocellular iron deposition, decreased Type I HH
macrophage iron, clevated transferrin saturation
Increased iron absorption, iron overload,
J32nï 3-2 microglobulin hepatocellular iron deposition, decreased Type 1 HH
macrophage iron, elevated transferrin saturation
Increased iron absorption, iron overload,
Usf2 Hepcidin hepatocellular iron deposition, decreased Type 2 HH
macrophage iron, elevated transferrin saturation
Hamp (liver Decreased iron absorption severe ironHepcidin
transgene) deflctency and anemia
Microcytic hypochromic anemia, tissue ironHpx Transferrin Atransferrinerniadeposition
TfR’ Transferrin Microcytic hypochromic erythrocytes, decreased
receptor-1 iron stores, embiyonic lethality
TfR12245x/245x Transferrin Increased iron absorption, iron overload Type 3 HH
rcceptor-2
Decreased iron absorption, systemic iron
b (Belgrade rat) DMT 1 (GI 85R) deficiency, impaired iron uptake in duodenum
and in_erythroid_precursors
Decreased iron absorption, systemic iron
mk DMTI(G185R) deficiency, impaired iron uptake in the —
duodenum and in_erythroid_precursors
Weh Hypochromic anemia, impaired iron transfer
—
. Ferroportin 1(Weissherbst) from yolk sac to embryo
-/- Iron accumulation in hepatocytes andCp Ceruloplasmin Aceruloplasminemia
macrophages
. Microcytic hypochromic anemia, impaired
sla Hephaestin
—
intestinal iron transfer
Elevated tissue and serum L-ferritin
Ftlf’ H-ferritin Embryonic lethality
—
Frda (fleuron Mitochondrial iron deposits, neurodegeneration
Frataxin Friedreich ataxia/heart knockout) and cardiomyopathy
Frda (muscle Mitochondrial iron deposits, cardiomyopathy
Frataxin Friedreich ataxiaknockout)
i Anemia, low serum iron levels, tissue ironHmoxl Hemeoxygenase 1 Hmoxl deficiencydeposition
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6. Iron metabolism and inflammation
One of the most obvious connections between iron metabolism and inflammation is the
necessity of iron for the devclopment of the immune system. Iron is reqtiired for the normal
proliferation and maturation of lymphocytes. Iron deficiency causes a reduction in
peripheral T-cell populations and atrophy of the thymus [114, 115]. In addition, the
relationship between iron and inflammation is generally recognized in certain baterial
infections and inflammations. Since iron is an important nutrient for the proliferation of
bacteria, the response of increased iron sequestration from bacteria becomes an important
host defense rnechanism. This section will illustrate the connection between iron
metabolisrn and the inflammation (anti-bacterial effect) in three aspects: structural
similarity of some proteins; regulation of iron metabolism by inflammatory cytokines; and
iron sequestration in bacterial infection.
6.1. Structural and functional similarities
The findings that there are structural similarities between sorne iron metabolism-related
proteins and proteins that are particularly important for inflammation suggest that there
may be a relationship between iron rnetabolism and inflammation. Three examples are
dernonstrated here: (i) hepcidin and defensin; (ii) Natural resistance-associated macrophage
protein 1 (Nramp]) and DMT1; and (iii) HFE and MHC class I.
6.1.1. Hepcidin and defensin
Hepcidin shares functional similanties with defensins. Antimicrobial peptides are a
valuable component of innate immunity in many species [116]. In mammals, antimicrobial
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peptides such as defensins [117] represent a substantial part of the immune system for
resistance to cellular pathogens. The bactericidal spectrum of hepcidin is similar to that of
hurnan defensin- 1, which can inhibit the proliferation of a range of pathogens including
Gram-negative Neisseria cinerea and the yeast Saccharomvces cerevisiae [105]. In
addition, hepcidin and defensin both appear in human blood [118], and the expression of
both can be induced by lipopolysaccharide, matching their roles in host defense.
In addition to these functional sirnilarities, hepcidin’s structural features are sirnilar to that
of antirnicrobial defensins in tenns of size and cysteine content [117, 119]. Hepcidin is a
small peptide with an approximate molecular mass of 3 kDa; defensins range from 4-6 kDa
in size. The hepcidin peptide sequence contains eight cysteine residues in four disulfide
bonds; the human f3-defensins have three intramolecular cysteine-bonds linldng cystcines 1-
5, 2-4, 3-6 [120] (Figure 8).
Figure 8. Protein alignment ofhuman defensins (defen B) and human hepcidin.
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6.1.2. NRAMP1 ana DMTY
The natural resistance of inbred mice strains to infection by Salmonelta typhinturium,
Mycobacteria, and Leishrnania donovaiti was documented nearly 30 years ago [121, 122].
A single locus (Bcg), mapped to mouse chromosome 1, has been shown to influence
bacterial replication in macrophages [123]. Positional cloning of Bcg identified the gene for
natural resistance-associated macrophage protein (NRAMF]) as being responsible for the
resistance to infection by bacteria [122].
The mammalian NRAMP family is divided into two classes, NRAMF] and DMT1 (also
known as NRAMP2). Although the cloning ofthe DMT1 gene was carried out afier that of
NRAMF] and its identification was based solely on its homology to NRAMF] (f igure 9),
the ftmction of DMT 1 was known before that of NRAMP]. A comparative study between
NRAMF] and DMT1 was aptly used to elucidate the function of NRAMP]. Since DMT1 is
a divalent cation transporter and can transport Fe2, Mn2, and Zn2 in several celi lines,
sirnilar studies have been performed on NRAMF] that showed that NRAMP1 can also
transport Fe2, Mn2, and Zn2, albeit with less efficiency than DMTY [58, 124, 125].
DMT1 and NRAMP1 are both located within endosomes and lysosomes [126, 127], which
ftirther suggests a functional similarity, although some NRAMP1 expression can also be
found within phagosomes [128, 129]. However, the ubiquitous expression of DMT1 in the
body, in contrast to the exclusive expression of NRAIVIP 1 within macrophage cells, points
to a difference of some ofthe functions ofthese two proteins [58, 130].
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Major controversy exists conceming the direction in which NRAMP 1 delivers iron ions.
Although DM11 has been demonstrated to transport Fe2 across the plasma membrane into
the celi cytoplasm, the iron transport direction of NRAMP 1 remains unclear. Two schools
of thought have emerged. One advances the hypothesis that NRAMP 1 functions to increase
intraphagosomal Fe2 in order to provide a catalyst for the Fenton reaction, which generates
the highly toxic hydroxyl radical for bactericidal activity [131]. The other hypothesizes that
the function of NRAMP 1 is to remove the fe2 required by intraphagosomal bacteria for
growth and the other divalent cations, such as Zn2 and Mn2, necessary for superoxide
dismutase thus providing an effective antioxidant defense [132].
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Figure 9. Protein alignment ofhuman NRÀIvIP1 and human DM11.
6.1.3. HFE and MHC class I
The HFE protein structurally belongs to the class I major histocornpatibility complex
(MHC) antigen, an important protein family in the immune system (Figure 10). The HFE
gene is located on chromosome 6p2l, close to the HLA class I gene cluster, and it encodes
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a MHC class I protein [133]. As with other MHC class I molecules, the extracellular
portion of HFE is composed of ai, a2 and a3 domains, and the a3 domain binds f32-
microglobulin [134]. The similarity between HFE and MHC class I molecules has raised
questions regarding the ftmction ofHFE. MHC class I molecules normally participate in the
cellular immune response by binding and presenting antigens to T-cells [135].
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Figure 10. Ribbon diagrams of HFE and MHC class I (MHC I) proteins. ai, a2, and a3
domain helixes of HFE and MHC I proteins are shown. (32m binds to both HFE and MHC
I. Transferrin receptor (TfR)-binding site on HFE and T-cell receptor (TCR)-binding site on
MHC I are indicated. (from reference: Lebron JA and Bjorkman PJ, 1999 [136])
6.2. Regulation of iron-metabolic proteins by inftammatory stimuli
Many iron-metabolic proteins can be regulated by vanous inflammatory stimuli. For
example, hepcidin synthesis in the liver and its secretion in the serum are known to be
increased by lipopolysaccharide (LPS) [107], turpentine [10$] and IL-6 [137]
administration in mice [13$, 139]. Ferritin transcription, translation and secretion are also
up-regulatcd by LPS [140, 141], turpentine [142] and IL-6 [143], as well as by TNFa and
interleukin la (IL-la) [144-146] in different tissues and cell types. IFN-y has been shown
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to up-reguiate DMT1 expression [147] and to down-regulate that of FP1 in the liver [14$].
Ail of these changes in iron metabolic proteins induced by inflammatory stimuli ultimateiy
iead to hypoferrernia and iron accumulation in the liver.
6.3. Iron seguestration from bacteria
It has been shown that animais injected with iron, when infected with dangerous bacteria,
dernonstrate an increased rate of mortality.
Bacteria are aiso iron-restricted species, and in muiticeiiuiar organisms colonized by
bacteria, there is no freeiy availabie iron for bacterial nutrition [149]. There are two general
rnechanisms by which bacteria obtain iron. The ftrst is characterized by direct contact
between the bacteria and an exogenous iron source. In this mechanism, iron is taken up
through bacterial ccii surface transporters. The second involves the synthesis and release of
iron-chelating compounds from bacteria into the extracellular medium and capture of these
compounds by their receptors. One known bacterial iron-chelating compound is caiied
siderophore [150]. Siderophore chelates iron with a very high affinity in order to extract
iron from most organic complexes.
In humans, severai iron-binding proteins, such as lactoferrin and lipocalin 2, are expressed
in an iron-unsaturated form. This iron-unsaturated form enabies the sequestering of iron as
a defence against invading bacteria.
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7. Recent findings inspiring our interest in studying Lcn2
Neutrophil gelatinase-associated lipocalin (NGAL) was first identified as a 25-kDa
glycoprotein associated with purified human neutrophil gelatinase [151]. Homologous
proteins were also identified in the mouse [lipocalin2(Lcn2)/24p3/utcrocalin] and rat (F32-
rnicroglobulin-related proteinlneu-related lipocalin) [152]. NGAL/Lcn2 has been shown to
be highly expressed in the colonic epithelial areas of inflammation, and its expression was
thought to be related to its anti-inflammatory ftinction [153]. The expression of Lcn2 in
utems during the implantation and parturition stages of pregnancy suggests that it may
function to induce apoptosis during involution [$2, 154, 155]. In addition, lipocalin 2 has
also been shown to induce apoptosis of a wide variety of leukocytes [156]. Furthermore,
microanay analyses performed in our laboratory two years ago obtained a spectnlm of
genes, including Lcn2, that could be modulated by different iron regulators.
Two categories of recent findings, combined with the results from microarray analysis,
inspired our interest in studying Lcn2.
The finding that NGAL/Lcn2 can function as an iron-binding molecule is supported by the
dernonstration that it mediates a transfenmn-independent iron uptake pathway activated
during kidney development [157]. fron delivered to differentiating epithelial cells by
NGAL/Lcn2 is capable of regulating iron-dependent genes, such as ferritin and transfenmn
receptor 1 (TfRÏ) [157], that are sensitive to the cellular iron status and are regulated by
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iron-responsive elements (IREs) [158, 159]. This finding indicates that such ceils can
utilize iron provided by NGAL/Lcn2. These observations, demonstrating that NGAL/Lcn2
mediates a transfenin-independent iron uptake pathway in vitro, raised thc question as to
whether this pathway can become activated in response to increased iron demand in in vivo
rodent models.
It lias also been shown that NGAL/Lcn2 binds catecholate-type bacterial ferric
siderophores [160], such as enterobactin. Siderophores have a high affinity for ferric iron
and are able to acquire iron from mainmalian iron-binding proteins, including transfenin
and lactoferrin [161]. Since NGAL/Lcn2 binds enterobactin with a higher affinity than the
E. cou enterobactin transporter, it effectively interferes with bacterial iron uptake in culture
conditions, and, in fact, acts as a bacteriostatic agent [160]. We have thus chosen to assess
lipocalin 2 expression in two models of inflammation: systernic (LPS) and local
(turpentine) inflammation, in evaluating its hypothesized bacteriostatic potential through an
iron depletion strategy.
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1. Objective
The purpose of this study is to investigate the role of Lcn2 in iron metabolism and
inflammation by assessing its expression profile under conditions of altered iron storage,
increased iron demand for hemoglobin synthesis, and induced iron redistribution during
inflammation.
2. Specific aims
Aim 1: To study lipocalin 2 expression in response to altered iron metabolism. Iron
absorption, storage, transport and utilization are regulated in response to altered iron
metabolism. Many iron-metabolic proteins can be regulated to perform their needed
ftinction and meet the body’s iron request. To define the role of Lcn2 in iron rnetabolism,
Lcn2 levels are assessed in different iron storage conditions by using mouse models of iron
overload and iron deficiency. The response of Lcn2 to an increased iron demand for
enhanced hemoglobin synthesis is assessed in mouse models of anemia and hypoxia.
Mouse rnodcls of anemia use PHZ (phenylhydrazine)-induced hemolytic anemia, iron
deficient anemia, and phlebotomy-induced anemia. The mouse model of hypoxia uses
CoC12-induced hypoxia. Lipocalin 2 mRNA in the liver and its secreted protein in the
senim are analyzed.
Aim 2: To investigate lipocalin 2 regulation during inflammation. Since Lcn2 was found to
bind bacteria-derived siderophore in vitro, the potential of Lcn2 to prevent bacteria growth
in vivo is promising. Thus we are interested in assessing Lcn2 expression in mouse models
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of bacterial component (LPS)-induced inflammations. Lcn2 transcription in the liver and its
secretion in the serum are analyzed in inflammation. Since the LPS-induced Lcn2 tissue
expression pattem may indicate the exact function of Lcn2 during inflammation, we are
thus interested in assessing the tissue expression pattem of lipocalin 2 during acute
inflammation. Lipocalin 2 mRNA levels are measured in the liver, spleen, duodenum,
heart, kidney, thymus, brain, bone manow, and in isolated hepatocytes and liver
mononuclear ceils. Lcn 2 expression in response to sterile inflammation is also assessed in
a turpentine (TP)-induced acute inflammation mode!. During inflammation, iron
redistribution and hypoferremia commonly occur; this is closely re!ated to the anemia of
chronic disease (ACD). b examine the mechanism ofhypofenemia and the role ofLcn2 in
the pathogenesis of ACD, Lcn2, DMT1, FP1 !eve!s are assessed in the liver of a mouse
mode! of anemia of chronic inflammations. Iron accumulation in hepatocytes and
macrophages are a!so analyzed to investigate their ro!es in the pathogenesis of
hypoferremia and ACD.
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Animais
Ail procedures were performed in accordance with the guidelines of the Canadian Council
on Animal Care and were approved by the Instimtional Animal Care Commiftee of the
Centre Hospitalier de l’Université de Montréal (CHUM). C57BL/6 female mice aged 3 or 8
weeks were purchased from Charles River Laboratories, Inc. (Wilmington, MA). Ail mice
were housed under strict specific pathogen-free conditions.
Animal treatrnents
Control mice were fed a standard commercial diet (Teklad Global 18% protein rodent diet,
Harian Teklad, Madison, WI). Dietary iron overload was produced by giving $-week-old
mice the same commercial diet supplemented with 2.5% (w/w) carbonyl iron (Sigma
Aldrich, St. Louis, MO) for 4 weeks. Iron deficiency was induced by feeding 3-week-old
mice an iron deficient commercial diet for 9 weeks. Ail mice were 12 weeks old at the time
of sacrifice.
To induce anemia through phlebotorny (PHL), 0.25 ml of biood was extracted by refro
orbitai puncture from anesthetized mice of 9 weeks of age. The procedure was repeated 24
hours later, and the animais were sacrificed by decapitation under sodium pentobarbital
anesthesia 16 hours afier the iast PHL.
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Hernolytic anemia was produced by intraperitoneal (i.p.) administration of 40 mg!kg body
weight of PHZ (Sigma-Aldrich), once daily for 4 days. The 9-week-old mice were
sacrificed the following day as previously described.
Cobalt chloride (C0C12)-induced hypoxia was elicited by i.p. injection of 60 mg/kg of
CoC12 (Sigma-Aldrich) dissolved in 0.9% saline. The 9-week-old mice were sacrificed after
24 hours as previously described.
Acute infectious inflammation was produced in 9-week old mice by a single dose of
lipopolysaccharide (LPS lOOjig i.p.) (Sigma Chemical, St Louis,) from Escherichia cou
serotype 055:B5. To induce sterile inflammation, a single dose of pure nondiluted
turpentine oil (100%) [TP 100ii subcutaneous (s.c.)J was injected into the back between
the scapulas of anesthetized 9-week old mice. Age-matched control mice were similariy
injected with an equivaient volume of sterile saline solution (0.09% NaC1). Animais were
sacrificed either 6 or 16 hours after the injection as previousiy described.
Long-term inflammation was produced by LPS injections over a 4-week period in mice (8-
12 weeks old): LPS 100 tg i.p., every 3 days for the first 8 injections, and LPS 50 ig i.p.,
daily for the final 7 injections. Animais were sacrificed 16 hours after the final injection as
previously described.
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Hematological measurements and transfenin saturation
EDTA-treated blood samples were obtained by orbital puncture under sodium pentobarbital
anesthesia. Red blood ccli (RBC) count, hemoglobin (Hb), hematocrit (HCT) and mean
corpuscular volume (MCV) were rneasured in an ABC vet counter (ABX hématologie,
Montpellier, france). Serum iron, total iron-binding capacity (TIBC) and transferrin
saturation were assessed by colorirnetric assays [162], using a Kodak Ektachem DT6O
system (Jolmson & Johnson, Ortho Ciinical Diagnostics, Mississauga, ON). TS was
calculated from the measured values of TIBC and SI.
Measurement of liver iron concentration
Liver iron concentrations were assessed by acid digestion of tissue samples, followed by
quantification of iron using atomic absorption spectroscopy, according to our previously
established rnethods [162].
Quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR)
Total liver RNA was isolated with Trizol reagent (Invitrogen, Burlington, ON) and reverse
transcription was performed using a Thermoscript RT-PCR system (Invitrogen). Levels of
lipocalin 2, hepcidin, glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and 3-actin
mRNA were rneasured by real-time PCR with a Rotor Gene 3000 Real Time DNA
Detection System (Montreai Biotech Inc., Kirkland, QC) and a Quantilect SYBRGreen I
PCR kit (Qiagen, Mississauga, ON). Ail primers were designed by Primer3 software such
that a minimum of 1 intron was included in each primer pair. The ampiified cDNA
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fragments for each primer pair were then verified by agarose gel electrophoresis to confirrn
the absence of the intron on the amplified fragment, and the absence of non-specific
products. The primers were: 5’-CCCATCTCTGCTCACTGTCC-3’ and 5’-
TTTTTCTGGACCGCATTG-3 for I ipocalin 2; 5’ -AGAGCTGCAGCCTTTGCAC-3’ and
5’ -GAAGATGCAGATGGGGAAGT-3’ for hepcidin; 5’-
TCAAGAAGGTGGTGAAGCAG-3’ and 5’-TGGGAGTTGCTGTTGAAGTC-3’ for
Gapdh; 5’ -TGTTACCAACTGGGACGACA-3’ and 5’ -GGTGTTGAAGGTCTCAAA-3’
for f3-actin; 5’-TTGCAGGGAGCCATCAGAG-3’ and 5’-
CAACCTAGTATTTAATAGCAAGATGC-3’ for DMT-l; and 5’-
CCCATCCCCATAGTCTCTGT-3’ and 5’-CTTGCAGCAACYGTGTCACC-3’ for FPI.
PCR amplifications were performcd in triplicate, according to the following program: 15
minutes at 95°C; 40 cycles at 94°C for 15 seconds, 55°C for 30 seconds, and 72°C for 30
seconds. The cycle thresholds, deftned as the value at which the amplification curve crosses
the threshold line obtained from a standard curve covering a range of four orders of
magnitude, were calculated automatically by the Rotor Gene data analysis software.
Lipocalin 2 and hepcidin mRNA expressions were then normalized to the Gapdh and 13-
actin expression levels.
RT-PCR
S amples of cDNA were obtained using the previously described method. Murine cDNA for
each sample was subjected to PCR amplification for lipocalin 2 expression (with forward
5 -GAAACCATGGCCCTGAGTGTC-3’ and reverse 5’-
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AGCCACACTCACCACCCATTC-3’ primers) and f3-actin expression (with forward 5’-
AGCCATGTACGTAGCCATCC-3’ and reverse 5’ ..TTTGATGTCACGCACGATTT-3’
primers) in the same tube. PCR was performed using Taq DNA polymerase (Arnersharn
Biosciences, Piscataway, NJ, USA) and a thermal cycler (Hybaid Omnigene; Jnterscience,
Markham, Ontario, Canada). The PCR amplification of lipocalin 2 gave a predicted product
size of 682 base pairs (bp), whcreas 13-actin yielded a product of 250 bp. The PCR reaction
mixture consisted of lx PCR buffer, 200 tM of each dNTP, 1.25 U of Taq DNA
polymerase, 50 pM of each primer for lipocalin 2 and 10 pM of each primer for 3-actin.
The PCR amplification was carried out as follows: an initial denaturation at 94°C for 10
mm; 35 cycles of 94°C for 45 seconds, 60°C for 1 mm, and 72°C for i mm; and a final
extension of 10 min at 72°C. The PCR products were electrophoretically resolved on a
1.5% agarose gel, stained with ethidium bromide, and then photographed. Lipocalin 2
levels are expressed relative to f3-actin levels.
Mononuclear cell (MNC) suspensions and hepatocyte isolation
Spleens were mashed through a 40 im nylon cell strainer, and erythrocytes in splenocyte
suspensions were lysed with Puregene RBC Lysis Solution (Gentra Systems, Minneapolis,
MN, USA). Mouse hepatocytes were isolated after liver perfusion with liver digest media
(GIBCO/BRL Life Technologies, Burlington, ON, Canada), followed by centrifugation on
Percoll gradient (Sigrna-Aldrich Canada Ltd., Oakville, ON, Canada), as described
elsewhere [163]. The hepatocytes were then washed with Williams media (GIBCO/BRL
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Life Technologies). Liver MNC suspensions were obtained by centrifugation of liver cmde
celi suspensionson Lympholyte-M (Cedarlane, Hornby, ON, Canada).
Western blotting for serum Lipocalin 2 detection
1.5 iL of serum was boiled for 5 min at 100°C in loading buffer containing 4% sodium
dodecyl sulfate (SDS), 20% glycerol, and bromophenol blue. Proteins were resolved on
12% SDS-polyacrylamide gel and transferred onto nitrocellulose membranes (Amersham
Biosciences, Baie d’Urfé, QC). The membranes were blocked with 6% nonfat dry milk
solution and incubated with anti-sip24/Lcn2 antibody [164] (a gifi from Dr. Marit Nilsen
Hamilton, Iowa State University). To detect immunocomplexes, peroxidase-conjugated
goat anti-rabbit IgG (Jackson hmnunoResearch Laboratories, Inc., Mississauga, ON) was
used as secondary antibody. Bands were visualized using an enhanced chemoluminescence
system from Arnersham Biosciences, Baie d’Urfé, QC.
Histopathology
Liver samples were fixed in buffered 4% formaldehyde and stained with
hematoxylinleosin. Ferric iron (Fe3) was detected by Prussian blue staining (Sigma
diagnostics, St Louis, MO), according to the manufacturer’s directions. The Prussian bÏue
color was enhanced with diaminobenzidine (DAB) (Sigma chemical, St Louis, MO).
Statistical analysis
Ail results are expressed as either group means ± SD (iron concentration, SI, TS, Hb, RBC,
HCT, MCV) or group means ± SEM (gene mRNA expression). Student’s t-test (unpaired,
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2-tailed) was used for comparison between treatments and mouse strains. Differences were
considered significant wherep < 0.05.
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Lcn2 mRNA expression in response to increased iron stores
Alterations in body iron stores are accompanied by changes in expression of the iron
regulator hepcidin [165], and of genes involved in cellular iron uptake and storage, such as
TfR and ferritin [166, 167]. To assess whether Lcn2 expression is regulated in response to
increased body iron stores, micc were fed an iron-enriched diet (2.5% carbonyl iron) for 4
weeks. This treatment led to an elevation of serum iron (22 ± 4 tM for the standard diet vs.
39 + 1 tM for the iron-enriched diet, p<O.Ol) and in transferrin saturation (45 ± 8% for the
standard diet vs. 96 ± 7% for the iron-enriched diet, p<O.Ol; Table 1). Iron loading was
further demonstrated by measuring liver iron concentrations that were found to be 4 times
higher in mice placed on the iron-enriched diet (286 ± 56 tg ironlg dry weight for the
standard diet vs. 1202 + 209 tg ironlg dry weight for the iron-enriched diet, p<O.Ol; Figure
la). Iron levels in the spleen were also significantly elevated (p<O.05, Figure la).
Lcn2 rnRNA expression was detected at very low levels in the livers of control mice on the
standard diet, and rernained unchanged in the liver (Figure lb) and spleen (data not shown)
of mice fed the iron-enriched diet. In contrast, liver mRNA levels of the putative iron
regulator hepcidin, used here as a control for the treatments, were significantly enhanced by
iron loading (p<O.O5, Figure lc).
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Figure 1. Iron stores, Lcn2 and hepcidin inRNA levels in mice fed a carbonyl iron
supplemented diet (n6 per group). (a) Iron concentrations in the liver and spleen ofcontrol
and iron-loaded mice (Fe). The resuits are expressed as means ± SD. Liver mRNA levels of
(b) lipoca[in 2 (Lcn2) and (c) hepcidin (Hamp) of mice fed a standard diet (control) and
carbonyl iron-supplemented diet (Fe). The resuits are expressed relative to Gapdh as group
means ± SEM. Student’s t test: p < 0.05; **p < 0.01.
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Table 1. Hematological indices, serum iron (SI) and transferrin saturation (TS) in iron-deficient and iron-Ioaded mice.
Treatrnent Hb (g/L) RBC (xlO’2/L) HCT (%) MCV (fL) SI (jiM) TS (%)
Control (n 6) 135 ± 5 9.6 ± 0.4 44 ± 1 46 ± 1 22±4 45 ± 8
Carbonyl iron — fe (n 6) 144 ± 7 9.3 ± 0.5 45 dz 2 48 ±2 39 ± 1 96±7
Irondeficiency—IDA(n=6) 124±5 9.0±0.3 38±1 42±1 18±2 35±7
p-value (control versus fe) <0.05 NS NS <0.01 <0.0 1 <0.0 1
p-value (control versus IDA) <0.0 1 <0.05 <0.0 1 <0.0 1 <0.05 <0.05
Data are presented as means dz SD. NS denotes non-significant differences.
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Lcn2 mRNA expression in response to iron deficiency anemia
We proceeded to examine the effects of decreasing body iron levels on the Lcn2 gene
expression by feeding mice an iron-deficient diet for 9 weeks. This treatrnent leU to the
Uevelopment of mild anemia and significant depletion of body iron stores, as revealed by
modest but statistically significant decreases in erytbroid parameters (Hb - 8%, RBC
- 6%,
HCT - 14%, and MCV
- 9%), semm iron and transferrin saturation (Table 1). In addition,
iron concentrations in both the liver and spleen were significantly reduced (liver - 286 + 56
tg ironlg dry weight for the standard diet vs. 159 ± 38 tg ironlg dry weight for the iron
deficient diet, p<O.Ol; figure 2a). The spleenlbody weight ratio in the iron-deficient mice
(5.0 + 0.48 spleen weight x 103/body weight) was significantly increased as compared to
untreated controls (4.1 + 0.14 spleen weight x 103/body weight, p<O.O5), which indicated
that erythropoiesis had been stimulated [168].
Lcn2 rnRNA levels were found to be elevated by 2.6-fold both in the liver (Figure 2b) and
spleen (data not shown), while hepcidin levels were reduced to 21% of the control (Figure
2c). Lcn2 protein was clearly detected in the serum of mice with iron deficiency anemia
(Figure 2d).
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Figure 2. Iron stores, liver Lcn2 and hepcidin mRNA levels and serum Lcn2 protein in
control and iron-deficiency anemic mice (n = 6 per group). (a) Iron concentrations in the
liver and spleen of control mice and mice with iron-deficiency anemia (IDA). The resuits
are expressed as means ± SD. (b) Lcn2 and (e) hepcidin (Hamp) mRNA levels in the liver
of control and iron-deficient anemic mice as determined by real-time PCR. The resuits are
expressed relative to Gapdh as means + SEM. Student’s t test: p < 0.05; **p <0.01. (d)
Relative changes in Lcn2 in serum measured by Western blotting. The anti-Lcn2
antibody[164] detected a band of approximately 24 kD.
Lcn2 expression is induced by acute anemia
The lack of Lcn2 mRNA modulation in response to increased tissue iron content and its
upregulation after exposure to an iron-deficient diet leading to the development of mild
anernia suggest that Lcn2 expression may rise with heightened erythroid dernand.
Therefore, we examined Lcn2 expression during anemia that was not caused by iron
59
deficiency. Iwo murine models of adute anemia were studied, phlebotomy (PHL)-induced
and phenylhydrazine (PHZ)-induced anemia.
l-lb, RBC, and HCT values in PHL mice were reduced by 63%, 66% and 67%, respectively
(Figure 3), while MCV was flot affected. In PHZ-treated animais, RBC and HCT values
were also markedly decreased (69% vs. control), Hb declined by 25% (Figure 3), and MCV
remained unchanged. km contrast to PHL-treated mice, hepatic iron levels, serum iron and
transfelTin saturation were rncreased in the PHZ-treated mice (data not shown), as PHZ
administration resulted in a large influx of iron into the liver Kupffer celis following
massive hemolysis.
Figure 3. Hematological indices in control, phlebotomized (PHL) and phenylhydrazine
(PHZ)- treated mice. (a) Hemoglobin (Hb) concentration, (b) red blood cells (RBC) and (c)
hernatocrit (HCT). The resuits are expressed as means ± SD for it6 animais per group.
Students t test: *p <0.01.
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The spleenlbody weight ratio of PHL mice (4.9 + 0.51 spleen weight x 103/body weight)
was significantly incrcased as compared to untreated controls (4.0 ± 0.1 spleen weight x
103/body weight, p<O.OS). Compared with control and PHL animais, mice treated with PHZ
showed far more severe splenomegaly (4.0 ± 0.1 for controls vs. 19.2 + 1.2 for the PHZ
treated group, spleen weight x 103/body weight,p<0.01).
Since we observed significant elevation in expression levels of the housekeeping gene
Gapdh by these treatments (particularly by PHZ), which were possibly due to ensuing
hypoxia [169], we uscd f3-actin as an internai control to calculate the relative amounts of
both Lcn2 and hepcidin mRNA by real-time PCR. We found that Lcn2 mRNA was
drarnatically increased in the livers of both PHL- (p<O.Ol) and PHZ-treated mice (p<0.0l;
figure 4a) as compared to control mice. Conversely, hepcidin expression was reduced by
80% in PHL-treated and by 72% in PHZ-treated mice (p<O.Ol; figure 4b), in agreement
with previously-reported data [165]. The Lcn2 protein was readily detected by Western blot
analysis in the sera of both PHL- and PHZ-treated mice (Figure 4c), but not in sera of the
controis.
These resuits dernonstrate that Lcn2 expression is strongiy induced during acute anemia.
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Figure 4. Lipocalin 2 (Lcn2) and hepcidin (Hamp) mRNA and protein levels in mice with
acute anemia (n = 6 per group). ta) Lcn2 and (b) Hamp mRNA content in the liver of
control, phlebotomized (PHL), and phenylhydrazine (PHZ)-treated mice as determined by
real-time PCR. The resuits are expressed relative to 13-actin levels as group means ± SEM.
Stcident’s t test. p < 0.01. (c) Relative changes in Lcn2 protein expression in serum as
detected by Western blotting.
Lcn2 expression is stimulated during CoC12-induced hypoxia
Anernia results in tissue hypoxia, which is a known activator of the expression of genes
involved in iron homeostasis, such as transferrin [170], TfR [171, 172], ferritin [173], and
ceruloplasmin [174]. To evaluate the effect of hypoxia on Lcn2 gene expression, mice were
treated with CoC12, a chemical inducer of hypoxia-like responses. As shown in Figure 5a, a
10-fold increase in liver Lcn2 mRNA expression (p<O.Ol) was observed 24 hours afier
CoC12 treatment, and an elevation of plasma Lcn2 protein levels was evident (Figure 5c).
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Conversely, hepcidin gene expression was strongly downregulated (Figure 5b, p<O.Ol), a
finding that is in agreement with previously reported data on liver hepcidin regulation in
mice exposed to low oxygen levels [165]. The down regulation of hepcidin gene expression
during iron deficient anemia, PHL-induced anemia, PHZ-induced anemia, and CoC12-
induced hypoxia represents the fiinction of decreased-hepcidin in facilitating iron absorb in
the duodenum and iron turnover in macrophages for RBC synthesis.
These results suggcst that tissue oxygenation may be a factor in Lcn2 gene regulation by
anemia.
b
t
C
C’,
Q)
X
C)
z
E
C’4
t
u
-J
Q)
>
C)
3
2
I
O
a
C
+
GO
(n
C’,
G)
C.
40
ç 20
I
G)
cl)
û O.F1
Control CoCI2
ri
Control CoCI2
Control CoCI2
Lcn2 : j
Figure 5. Lipocalin 2 (Lcn2) and hepcidin (Hamp) levels in hypoxic mice. (a) Lcn2 and (b)
Harnp rnRNA content in the liver of control, and cobalt chloride (C0C12)-treated mice as
detennined by real-time PCR. The resuits are expressed relative to j3-actin levels as group
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means ± SEM. Student’s t test. p < 0.0 1. (c) Relative changes in Lcn2 protein expression
in serum as detected by Western blotting.
Lcn 2 expression is up-regulated by LPS and turpentine in the liver.
We treated mice with LPS in order to provide a systemic inflammatory stimulus that
rnimics bacterial infection. LPS is a membrane glycolipid component of Gram-negative
bacteria and exhibits strong immunostimulatory activity in mammals. To generate an acute
inflammation model, C57BL/6 mice were administered a single dose of LPS (100 jig, i.p.),
and after 16 hours, blood and tissue samples were collected. It has been shown that the liver
is a major site of Lcn2 synthesis, and the Lcn2 protein is secreted from the liver into the
serum. Thus, we rneasured Lcn2 mRNA levels in the liver and Lcn2 protein levels in the
senim. After a single LPS injection, Lcn2 gene expression in the liver was increased by
approximately 124 times during acute inflammation relative to controls (figure 6a). Lcn2
protein was strongly detected in the serum of LPS-treated mice, but almost undetectable in
the serum of control mice (Figure 6c). As seen in most inflammatory conditions, sernm iron
(SI) and transfenin saturation (TS) were significantly decreased in the serum during acute
inflammation (control versus LPS acute inflammatory, SI 16±2 imo1/L vs. 5±1 jimol/L,
p<O.Ol, and TS 37±6% vs. 14±3%, p<O.Ol). In the acute inflammation model, hepcidin
mRNA was increased (2.1 times, p<O.O 1), in agreement with previous reports (Figure 6b).
To determine whether Lcn2 expression can be regulated in localized inflammation, a
turpentine (TP) model was used to induce a sterile local tissue abscess. Mice were
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subcutaneously injected in the back with 100 jil turpentine. Liver and serum samples were
collected 16 hours later. As shown in figure 6a, Lcn2 expression is 102 times increased
(p<O.Ol) in the liver by turpentine treatment, as compared to the control. Increased level of
Lcn2 proteins were formed in the serum (figure 6c) of turpentine-treated mice, whereas
Lcn2 levels were flot detected in the serum of control mice. Hypoferremia was also
observed in turpentine-induced inflammation. Serum iron and transferrin saturation were
both significantly decreased by TP treatment (control vs. acute TP inflammation, SI 16±2
amo1/L vs. 10±2 jimol/L, p<O.Ol, and TS 37±6 % vs. 26±3%, p<O.Ol). In this turpentine
induced acute inflammation, hepcidin mRNA was increased (4.8 times, p<0.Ol), which is
consistent with previous reports (Figure 6b).
These resuits suggest that Lcn2 expression can be increased by both systemic (LPS) and
local (turpentine) inflammation.
a b
s
2iL
—
C
Conirol LPS-16h TP-16h
Lcn2
*
*
*
*
65
Figure 6. Lipocalin 2 (Lcn2) and hepcidin (Hamp) levels in mice of LPS- and turpentine
(TP)-induced acute inflammation, ta) Lcn2 and (b) Hamp mRNA content in the liver of
control, and LPS- and turpentine-treated mice as determined by real-time PCR. The resuits
are expressed relative to Gapdh levels as group means ± SEM. Student’s t test: * p<0.01.
(c) Relative changes in Lcn2 protein expression in sernm as detectcd by Western blotting.
Tissue expression pattern of Lcn2 during acute inflammation.
It has been shown that liver is the major organ for Lcn2 synthesis during infection [175].
To determine whether Lcn2 can be indticed in other organs during infection, we measured
the expression of Lcn2 in a variety of tissues during acute inflammation. In this study,
different tissues from mice were collected 16 hours following a single injection of LPS
(100 tg, i.p.). RT-PCR resuits of each tissue or ceil-type were repeated three times from
three different mice. Starting cDNA amounts were well controlled by fine mRNA
quantification and dilution. One of the experirnent resuits is shown in Figure 7 from three
equal results. In saline-treated controls, basal Lcn2 mRNA expression was observed in the
lungs, bone rnanow, thymus, brain, spleen, and liver (in order of highest to lowest
expression, but flot in the duodenum, heart, lddney or muscle (Figure 7). In mice 16 hours
post-LPS injection, Lcn2 rnRNA levels were up-regulated well beyond the basal expression
profile in the lungs, bone marrow, thymus, brain, spleen, and liver. In addition, Lcn2
mRNA was strongly detected in the duodenum, heart, lddney and muscle (Figure 7). In
order to investigate the ceil type-specific expression of Lcn2 in the ilver, hepatocytes and
liver mononuclear cells (MNC) were isolated from the livers of LPS- and saline-treated
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mice. As shown in Figure 7, Lcn2 mRNA was expressed in hepatocytes, but flot in the
MNCs, of control mice. Following LPS treatment, Lcn2 expression was up-regulated in
both hepatocytes and MNCs (Figure 7).
This resuit suggests that Lcn2 expression is increased in most tissues during acute
inflammation.
Lcn2 expression in different tissues
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Figure 7. Tissue expression pattem of Lcn2 in control and LPS-induced acute inflammatory
mice. Lcn2 and f3-actin mRNA are determined by RT-PCR, from (upper panel) control and
(lower panel) LPS-treated mice. Lcn2 expression (upper bands) is assessed relative to f3-
actin expression (lower bands) for each sample.
Lcn2 expression in response to anemia of chronic inflammation
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Anernia of chronic disease (ACD) is the second most common form of anemia. ACD
develops under chronic inflammatory disorders such as chronic infections, cancer or
autoimmune diseases [10]. In this ACD model, LPS was administered every 3 days (100
jig, i.p.) for the first 8 injections, and then daily (50 tg, i.p.) for the 7 final injections over a
period of 4 wceks. Samples were collected 16 hours after the last injection. As seen in
figure 8a, Lcn2 transcription was strongly increased in the liver. Lcn2 protein was also
rnarkedly increased in the scrum during chronic inflammation (figure 8b). Serum iron and
transferrin saturation were both significantly decreased (control vs. chronic inflammation,
Si 19±4 imol/L vs. 15±3 iimol/L, p<O.O5, TS 40±7% vs. 24±5%, p<O.Ol). In this model,
we also observed that mice developed anemia, in which hemoglobin, red blood celi count,
and hernatocrit decreased by 34%, 39%, 40% relative to controls, respcctively (Table 2).
Mean corpuscular volume was flot significantly affected.
These resuits demonstrate that Lcn2 expression is up-regulated during anemia of chronic
inflammation.
a b
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figure 8. Lipocalin2 (Lcn2) levels in chronic inflammatory mice. (a) Lcn2 mRNA content
in the livers ofcontrol and 4-week LPS-treated mice as detennined by RT-PCR. The results
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are expressed relative to F3-actin levels. (b) Relative changes in Lcn2 protein expression in
senim as detected by Western blolling.
Table 2. Hematological indices in mice injected with LPS for 4 weeks.
Hb, g/L RBC,xTLHCT,%MCV, fi
135±5 9.6±0.4 44±2 46±1
89±7 5.8±0.5 27±2 45±1
<0.01 >0.05p-value <0.01 <0.01
Data are presented as means ± SD
Liver iron accumulation during inflammation is related to changes in DMT1 and FP
expression and in macrophage infiltration.
It has been shown that iron can accumulate in macrophages during inflammation [176),
which in part explains the mechanism of hypoferremia which occurs upon inflammation.
The disturbance in iron distribution contributes to the pathogenesis of ACD, in which iron
becomes less available for erythropoeisis. To ftirther investigate the mechanisms of
hypoferremia, liver iron concentration was assessed in inflammatory mouse models. Iron
was significantly accumulated in the livers of 6-hour acute inflammatory mice (control vs.
LPS-6h, iron concentration in the liver 3 17±30 j.ig ironlg dry weight vs. 396±4 1 g ironlg
dry weight, p<O.Ol) (Figure 9a). In chronic inflammatory mice (control vs. chronic
Treatment
Control-4wk (n=6)
LPS-4wk (n5)
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inflammation, iron concentration in the liver was 286±23 tg ironlg dry weight vs. 452±13
ig ironlg dry weight,p<O.O1) (figure 9b).
To understand which type of liver celis accumulated iron, we applied an enhanced Prussian
blue staining technique to paraffin-embedded siides of the liver. In control mice livers,
parenchymal celis were lightly stained, as shown in figure 9e. In contrast, the livers of
chronic inflammatory mice showed heavy iron staining in hepatocytes (Figure 9f). In
addition, a strong staining of macrophages was observed (Figure 9g), whereas it was flot
obseiwed in samples from control mice (figure 9e).
DMT 1 and FP 1 are two iron ion transporters located on the cellular membrane of both
hepatocytes and macrophages. In cellular homeostasis, iron uptake is mediated by TfR and
then delivered by DMT1, and iron export is mediated by FP1. To understand the
inechanism by which iron is increasingly accumulated in the liver, we assessed the status of
these two iron transporters. DMT1 transcription was increased 2.9 (p<O.Ol) times or 1.6
tirnes (p<O.Ol) in the liver, in 6 hour or 16 hour LPS-induced acute inflammatory models,
respectively, which suggests an increased iron uptake by hepatocytes (Figure 9c). fP1
transcription was decreascd by 98% or 89% (p<O.Ol) in the same 6 hour or 16 hour
paradigms, respectively, which suggest decreased iron export (Figure 9d). It is possible that
the changes in DMTY and fPl expression co-operate together resulting in increased iron
accumulation in the liver.
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These resuits show that iron is accumulated in the liver of acute and chronic inflammation,
and iron accumulates in both hepatocytes and macrophages. These resuits suggest that such
iron accumulation is achieved, at least in part, in a co-operative manner by the regulation of
two iron transporters, DMT1 and FPI.
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Figure 9. Iron concentrations, DMT1 and fPY levels, and iron deposition in the liver of
control and inftammatory mice. Iron concentrations in the livers of LPS-induced (a) acute
and (b) chronic inflammatory mice. (c) DMTY and (d) FP1 mRNA content in the liver of
control and LPS-induced 6 and 16 hour acute inflammatory mice as determined by real
tirne PCR. The resuits are expressed relative to Gapdh levels. Columns represent group
means ± SEM. Student’s t-test: * p<0.0i. Light micrographs ofrepresentative liver sections
from (e) control and (f-g) chronic inflammatory mice. (g) Macrophages are indicated with
arrows. Iron accumulations in hepatocytes and macrophages are shown by enhanced
Pnissian blue staining ofthe liver section. Original magnification 600x.
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1. Discussion
The present study investigated the regulation of Lcn2 expression in murine models of
altered iron homeostasis. Adaptive responses of Lcn2 to iron stores, anernia and
inflammation were examined. Lcn2 expression was increased in mouse models of anemia,
hypoxia, and inflammation, but was flot altered in dietary iron overload. The observations
that both anemia- and hypoxia-induced Lcn2 expression at the mRNA and protein levels
suggest that Lcn2 may serve as an iron trafficking protein during periods of enhanced
erythroproiesis. In addition, the induction of Lcn2 expression in response to inflammatory
stimuli supports a hypothesized role for Lcn2 in the inhibition of bacterial proliferation
through an iron depletion strategy.
Lcn2 was initially found to be associated with iron metabolism due to its capacity for iron
delivery. The existence of a transfenin-independent iron delivery pathway was provided by
the observation that 1fR knockout mice are stili able to initiate tissue development, and
thus presumably obtain iron by an alternative iron-uptake mechanism [177]. This notion is
further supported by recent reports of a Lcn2-mediated, transfenin-independent iron
delivery pathway believed to be active during early development [157, 160].
The resuits in mice with anemia induced by either iron-depletion, phlebotomy (PHL) or
PHZ-treatment clearly demonstrate that Lcn2 is induced in the liver in response to anemia.
This suggests that a Lcn2-mediated iron delivery pathway in the liver can be activated
when the iron dernands of erythropoiesis increases. The up-regulation of Lcn2 appears to
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be independent of the status of liver iron stores. PHL did flot significantly alter liver iron
stores in these studies whereas PHZ- treatment led to an increase in liver iron
concentrations and serum iron (because of hemoglobin release from lysed RBC); yet both
treatrnents strongly induced Lcn2 expression. Moreover, Lcn2 expression was not affected
by iron-loading, since mice fed an iron-enriched diet did flot show any changes in Lcn2
levels. In both PHL- and PHZ-induced acute anemia, Lcn2 upreguation might be modulated
by four possible mechanisms: increased request of erythropoiesis, increased EPO release in
the serum [17$, 179], the activation ofGATA-1 element on Lcn2 and/or tbrough hypoxia.
The regulation of Lcn2/NGAL during anemia possibly occurs via cis-acting regulatory
elernents, such as the binding site for GATA-l found in the 5’-flanking region of the
Lcn2/NGAL gene [180]. GATA-1 is a zinc finger transcription factor that plays a central
role in erytbroid development, as evidenced by the fact that GATA-l-deficient mice die
prenatally from severe anemia [181], with arrest of erythroid maturation at a
proerythroblast-like stage [182]. Jnterestingly, many promoters of genes involved in
cellular iron uptake and storage, such as TfR and fenitin, contain cis elements recognized
by the GATA-1 factor [183]. This transcriptional regulation of iron-related genes likely
ensures coordinatcd regulation of iron availability and hemoglobin synthesis. In this
context, activation ofthe Lcn2-mediated iron transport pathway by anemia could contribute
to rapid mobilization of iron from iron-storing celis to supply sufficient amounts of the
element for erythropoietic activity.
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Our resuits in anemia/hypoxia models indicate that Lcn2 levels may also be regulated by
the level of tissue oxygenation. CoC12 mimics hypoxic induction of the hypoxia inducible
factor (HIF-1), which activates transcription by binding to hypoxia responsive elements.
While hypoxia is known to induce the expression of both transfenin and TfR via HIF-1
[170-172], recent evidence indicates that transferrin-dependent iron uptake, however, does
flot significantly change during hypoxia [173J. Jnstead, as shown in rat myocardial [184]
and human embryonic lddney celis [173], hypoxia induces an as yet to be identified
transferrin-independent iron uptake pathway. Stimulation of iron uptake via the Lcn2
pathway by hypoxia could allow cells to sequester iron in amounts sufficient to maintain
enzyme ftrnction and cellular survival during periods of low oxygen concentration.
In addition to our finding that Lcn2 can respond to anemia and hypoxia, Lcn2 also appears
to be capable ofresponding to inftammatory stimuli.
A wide range of bacteria can use synthesizcd siderophores to obtain iron from the infected
host for proliferation [185]. Siderophores take advantage of their high affinity for iron, and
are able to chelate iron not only from iron-containing proteins but also from iron
sequestration proteins including transfenin and lactofenin. The recent finding that
marnrnalian-derived lipocalin 2 can bind to bacteria-derived siderophores suggests a new
host-defence mechanism of the innate immune system.
Our results are in agreement with previous study showing that Lcn2 was strongly induced
by a Gram-negative bacterial component, LPS, produced from E. cou. This result indicates
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that Lcn2 is expressed in response to bacterial infection. This bacteria-specific response is
consistent with reports that a human Lcn2 homologue, NGAL, is highly secreted in the
senim of bacteria-infected patients [186].
Turpentine-induced tissue injury generates a local inflammatory condition which is
characterized by increased IL-l -dependent IL-6 production [187, 18$]. The finding that
Lcn2 was induced by turpentine injection indicates that Lcn2 can be up-regulated by local
inflammation. Since cancers have been shown to be closely associated with chronic
inflammation [189], this aseptic response of Lcn2 may explain the observation that
Lcn2/NGAL mRNA is up-regulated in neoplastic tissues, such as colon cancer, lung
adenocarcinomas, mucin-producing tumors and pancreatic cancers [190].
In saline-treated controls, basal Lcn2 mRNA expression was observed in the thymus,
spleen and lungs. The thymus and spleen are two important organs for the immune system,
and the lungs are in direct contact with environmental pathogens in the air. Basal Lcn2
mRNA expression was detected in these tissues, in accordance with the postulated role of
Lcn2 in the host-defence mechanism of the innate immune system.
Lcn2 mRNA expression was increased by LPS in almost all of the tissues examined. This
broad induction of Lcn2 suggests a new mechanism of tissuc-based defence against
invading bacteria, distinct from the traditional serum-based defence afforded by the iron
sequestration protein lactoferrin. Iron is a required nufrient for bacterial proliferation, and
the appearance of Lcn2 both in the semm and in the tissues suggests that the iron
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sequestration potential of Lcn2 can flot only limit the survival of bacteria in the circulation,
but also inhibit bacteria that have already invaded the ceils.
The antimicrobial activity of Lcn2 has been shown to be dependent upon its ability to bind
bacteria-derived enterochelin-like siderophores [81]. By using Lcn2 knockout mice, a
recent experiment proved that the antibacterial activity of Lcn2 is attributed to its iron
sequestration effect through its binding to iron-laden siderophores, and this effect is
siderophore-specific to enterochelin-dependent bacteria [191]. The enterochelin-specific
prevention of bacterial growth by Lcn2 suggests that Lcn2 can effectively protect against
those bacteria that produce the enterochelin-like siderophore, such as E. cou, $aÏmoneÏÏa
spp., BruceÏla abortus, BaciÏhts anthracis, Burkhodria cepacia, Corynebacteriïtm
dtphtheriae, Paracoccus spp. and Vibrio spp. This characteristic of Lcn2 highlights the
potential of artificially synthesised Lcn2 protein or Lcn2 mimetics in future clinical
applications.
In the chronic inflammation mouse model, anemia was induced by a 4-week LPS treatment,
which mimics ACD. Decreased serum iron levels were seen in both acute and chronic
inflammation. The duration of hypofenemia contributes to the pathogenesis of anemia, by
which the iron availability for RBC synthesis is decreased. On the other hand, this
hypoferremia creates an iron depletion strategy which prevents bacterial proliferation.
Increased iron accumulation was obsewed in both macrophages and hepatocytes. This
accumulation highlights the occurrence of iron disturbance during chronic inflammation,
and the subsequent generation of hypofenemia. Given that DMT 1 and FP 1 are both
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expressed in macrophages and hepatocytes [192-194], an increascd iron uptake, in part,
through the up-regulation of DMT 1 and a decreased iron export through the down
regulation of FP 1 in the liver suggests a mechanism for iron accumulation in both types of
celis. It has bcen shown that increased iron storage through the up-regulation of ferritin
synthesis by inflammatory cytokines also facilitates iron accumulation in macrophages
[144]. The generation of anemia during chronic inflammation may also involve other
mechanisms. for example, cytokines may impair erythrocyte survival [195] and may also
stirnulate erythrophagocytosis by macrophages [196]. Whether the increased Lcn2
expression during chronic inflammation contributes to the iron accumulation in hepatocytes
and macrophages remains to be elucidated.
2. Conclusions
In conclusion, the work presented here indicates that Lcn2 is stimulated by anemia, hypoxia
and inflammation. The up-regulation of Lcn2 in anemia and hypoxia suggests that Lcn2
may have an important physiological role in the regulation of iron availability for
hemoglobin synthesis and for cellular survival. Lcn2 up-regulation during inflammation is
in agreement with an iron sequestration role in the inhibition of bacterial proliferation.
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In this smdy, Lcn2 has been shown to be able to respond to anemia, hypoxia and
inflammation. Thus, further research should concentrate on investigating the mechanisms
ofthese responses.
Lcn2 expression was induced in two mouse models of anemia: phlebotomy and PHZ
treatment. Since erythropoietin (EPO) is usua!ly up-regulated under anemic conditions, the
question of whether Lcn2 is regulated by EPO is of interest. An experiment assessing the
expression levels of Lcn2 in EPO-treated mice will answer this question. Since Lcn2 is
synthesized in the liver, hepatocyte cultures can be used as an in vitro mode!. To examine
the influence of iron levels on Lcn2 expression, iron (ferric citrate) or the iron chelator
desferrioxamine (DFO) can be added to the hepatocyte culture. The influence of EPO on
Lcn2 expression can also be tested in this hepatocyte culture mode!. In addition, during
enhanced erythropoiesis, GATA1, a zinc finger transcription factor, is required for normal
erythroid development by binding to the promoter region of several genes and promoting
their transcription. To examine whether Lcn2 can be activated by GATA1, a GATA1
binding assay can be performed on the promoter region of Lcn2 using electrophoretic
rnobility shifi assays (EMSA). If GATAY can bind to the Lcn2 gene and prornote Lcn2
transcription, further identification of proteins involved in GATA1 -Lcn2 activation is of
interest. The activation of the GATA1 pathway should include several other upstream
proteins. Different inhibitors for candidate proteins can be added to the hepatocyte culture,
thus identifiying putative proteins involved in GATA1 pathway activation and subsequent
Lcn2 transcription.
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Cobalt chloride-induced hypoxia condition has been shown to increase Lcn2 mRNA
expression. CoC12 mimics hypoxia by increasing the level of hypoxia inducible factor 1
(141f-1). 141F-1 is a master regulator ofthe cellular adaptive response to hypoxia. However,
to exciude other effects of cobalt chloride on Lcn2 expression, a low oxygen (10% 02)-
induced hypoxia mouse model can be used to assess Lcn2 expression. The low oxygen
condition can also be carried out on the hepatocyte culture to assess its influence on Lcn2
expression. b provide molecular evidence of the influence of HIF-1 on Lcn2 expression,
an HIF-1 binding assay will be performed on the promoter region of Lcn2 with EMSA
techniques. If HIF- 1 can bind to the Lcn2 gene and promote its transcription, the further
identification of proteins involved in the HTF-1-Lcn2 activation pathway would be of
additional interest. Different inhibitors of candidate proteins in the HIF-1 pathway can be
added to the hepatocyte culture, and the involvement of these proteins can thus be shown
using Lcn2 transcription and HIf-1 binding assay.
LPS has also been shown to increase Lcn2 expression. The toli-like receptor 4 (TLR4) has
been found to be the receptor for LP$. To assess whether LPS-induced Lcn2 expression
depends on TLR4, a TLR4 spontaneous mutant mouse strain (C3H/HeJ mice [197, 198])
can be used to analyze Lcn2 expression after LPS injection. Upon activation, TLR4 can
subsequently activate the NF-icB pathway. To assess whether the LPS-induced Lcn2
expression dcpends on the NF-KB pathway, an NF-icB pathway inhibitor, pyrrolidine
dithiocarbamate (PDTC), can be used to analyze Lcn2 expression during LPS treatment.
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Furthermore, since the activation of the NF-KB pathway by LPS involves several proteins,
the identification of each of the proteins necessary for Lcn2 expressions is also of interest.
Different inhibitors for candidate proteins can be added to LPS-stimulated hepatocyte
cultures. Lcn2 transcription and translation can then be assessed and compared to controls.
Molecular evidence of the NF-KB-activated Lcn2 transcription can be analyzed by an NF
KB binding assay through EMSA techniques.
Questions addressing the exact flinctions of Lcn2 up-regulation in anemia, hypoxia and
bacterial infection can be fiirther investigated by studying Lcn2 knockout mice to
demonstrate the need for Lcn2 in these conditions. The role of Lcn2 in iron sequestration
during anemia of chronic inflammation can also be elucidated by studying Lcn2 knockout
mice.
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